Moderní farmakoterapie Jessenius
19 stran : barevné ilustrace ; 23 cm
- MeSH
- Autoimmune Diseases MeSH
- Biological Therapy MeSH
- Infliximab pharmacokinetics pharmacology therapeutic use MeSH
- Publication type
- Review MeSH
- Conspectus
- Farmacie. Farmakologie
- NML Fields
- farmacie a farmakologie
- alergologie a imunologie
Terapie v gastroenterologii a revmatologii ; prosinec 2022
20 stran : ilustrace ; 30 cm
Brožura obsahuje práce přednesené na kongresu, který se zaměřil na použití biosimilars and biobetters v léčbě střevních nemocí. Určeno odborné veřejnosti.
- MeSH
- Biological Therapy MeSH
- Biosimilar Pharmaceuticals therapeutic use MeSH
- Infliximab therapeutic use MeSH
- Injections, Subcutaneous MeSH
- Intestinal Diseases therapy MeSH
- Publication type
- Congress MeSH
- News MeSH
- Conspectus
- Farmacie. Farmakologie
- NML Fields
- farmacie a farmakologie
- farmakoterapie
- gastroenterologie
- NML Publication type
- brožury
Antagonisti tumor nekrotizujúceho faktoru α sa v súčasnosti bežne používajú v liečbe stredne ťažkej až ťažkej formy Crohnovej choroby a ulceróznej kolitídy. Približne 50 % pacientov s nešpecifickými zápalovými ochoreniami čreva, ktorí v úvode profitovali z liečby antagonistami tumor nekrotizujúceho faktoru, po čase stratí liečebný účinok. Účinnosť liečby je vysoko závislá od farmakokinetiky a farmakodynamiky. Terapeutické monitorovanie liečiva (TDM – therapeutic drug monitoring), ktoré predstavuje meranie hladiny liečiva ako aj protilátok proti liečivu (ADAb – anti-drug antibodies), je novým prístupom optimalizácie liečby a dosiahnutia najnižšieho rizika straty odpovede. V súčasnosti nie je jasné presná terapeutická hladina, ktorá by zodpovedala klinickej odpovedi. Produkcia ADAb môže viesť k poklesu hladín až neutralizácii liečiva s následnou stratou liečebného účinku. Rovnako môžu ADAb prispieť k infúznym reakciám, tromboembolickým príhodám a sérovej chorobe. Predkladaný článok skúma vývoj TDM pri liečbe IBD. Skúma hlavné tvrdenia o TDM ako aj vývoj ich používania v poslednom období, skúma terapeutické rozmedzie, stratu odpovede a opisuje súčasné trendy v klinickej praxi.
Tumor necrosis factor-α antagonists are currently widely used in patients with moderate to severe Crohn's disease and ulcerative colitis. Approximately 50% of patients with inflammatory bowel disease who initially benefit from treatment with tumor necrosis factor antagonists eventually lose response. However, the action of the drug and its efficacy are greatly dependent on pharmacokinetics and pharmacodynamics. Therapeutic drug monitoring (TDM) is a new approach that measures drug trough levels and anti-drug antibodies (ADAbs) to optimize treatment and achieve the best strategy in the case of loss of response. Currently, there is no clear cut-off trough level value that corresponds to the clinical response. ADAb production can cause a drop in trough levels or neutralize the drug, resulting in a loss of response. ADAbs can also contribute to infusion and injection reactions, thromboembolic events, and serum sickness. This review examines the evolution of TDM in the treatment of inflammatory bowel diseases. It also explores the main contentions and developments surrounding the use of TDM in recent years, such as trough level and loss of response, and describes the current trends of TDM in clinical practice.
- MeSH
- Biological Therapy methods MeSH
- Inflammatory Bowel Diseases * drug therapy MeSH
- Infliximab pharmacology therapeutic use MeSH
- Humans MeSH
- Drug Monitoring methods MeSH
- Check Tag
- Humans MeSH
- Publication type
- Review MeSH
BACKGROUND: CT-P13 is a biosimilar drug of reference infliximab and is approved in some countries for use in some indications for which reference infliximab is approved, including inflammatory bowel disease (IBD). The CT-P13 formulation is identical to that of reference infliximab and has similar physiochemical characteristics. However, even a small molecular distinction could lead to different behavior of CT-P13 in immunoanalytical detection systems. AIM: To determine the correlation between three different enzyme-linked immunosorbent assays for infliximab detection in the measurement of CT-P13 trough serum levels. METHODS: Serum samples (n = 42) from IBD patients (n = 22) treated with CT-P13 Remsima™ (Celltrion, Korea) were evaluated in a blinded way in infliximab assays manufactured by (A) Matriks Biotek (Turkey), (B) Theradiag (France), and (C) R-Biopharm (Germany). RESULTS: All assays showed excellent qualitative correlation (Cohen's kappa = 0.90 for A vs. B, 0.76 for A vs. C, and 0.83 for B vs. C). A linear quantitative correlation was satisfactory as well (Spearman's r = 0.91 for A vs. B, 0.86 for A vs. C and 0.92 for B vs. C). Assay C did not detect CT-P13 in 6 samples detected by A and/or B. CONCLUSION: There is a good correlation of CT-P13 serum level detection between these assays.
- MeSH
- Inflammatory Bowel Diseases blood drug therapy MeSH
- Immunoassay methods MeSH
- Infliximab administration & dosage pharmacokinetics MeSH
- Humans MeSH
- Drug Monitoring methods MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
Autor uvádí přehled psoriatické artritidy zahrnující její epidemilogii, klinický obraz, klasifikaci a seznamuje s léčbou klasickou a nově nastupující léčbou biologickou.
Author gives a review on psoriatic arthritis including epidemiology, clinical picture and classification and informs about classical and newly introduced biologic therapy.
- Keywords
- Etanercerpt, Onercept,
- MeSH
- Adalimumab MeSH
- Infliximab MeSH
- Humans MeSH
- Antibodies, Monoclonal administration & dosage MeSH
- Arthritis, Psoriatic etiology drug therapy radiography MeSH
- Check Tag
- Humans MeSH
- Keywords
- ETANERCET, LENERCEPT,
- MeSH
- Cytokines adverse effects drug effects MeSH
- Infliximab MeSH
- Interleukin-10 chemical synthesis therapeutic use MeSH
- Humans MeSH
- Antibodies, Monoclonal therapeutic use MeSH
- Arthritis, Rheumatoid physiopathology therapy MeSH
- Check Tag
- Humans MeSH
- Publication type
- Review MeSH
